Antitumor Effect of Bevacizumab in a Xenograft Model of Canine Hemangiopericytoma

Masaki Michishita; Tatsuya Uto; Ryota Nakazawa; Hisashi Yoshimura; Kikumi Ogihara; Yuko Naya; Tsuyoshi Tajima; Daigo Azakami; Seigo Kishikawa; Toshiro Arai; Kimimasa Takahashi

doi:10.1254/jphs.12268SC

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Antitumor Effect of Bevacizumab in a Xenograft Model of Canine Hemangiopericytoma

Masaki Michishita, Tatsuya Uto, Ryota Nakazawa, Hisashi Yoshimura, Kikumi Ogihara, Yuko Naya, Tsuyoshi Tajima, Daigo Azakami, Seigo Kishikawa, Toshiro Arai, Kimimasa Takahashi

著者情報

キーワード: bevacizumab, canine hemangiopericytoma, vascular endothelial growth factor (VEGF)

ジャーナルフリー早期公開

論文ID: 12268SC

DOI https://doi.org/10.1254/jphs.12268SC

この記事には本公開記事があります。

The final version of this article is now available: Vol. 121 (2013), No. 4 pp. 339-342

詳細

抄録

Canine hemangiopericytoma (CHP) is characterized by frequent local recurrence and increased invasiveness. Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis in tumors. The aim of the present study was to investigate the effect of a single dose of bevacizumab on a xenograft model of CHP. VEGF protein was secreted from cultured CHP cells and interacted with bevacizumab. Bevacizumab treatment suppressed tumor growth by inhibiting tumor angiogenesis, whereas no significant differences were observed in the proliferation index and apoptosis rates of treated and untreated mice. Thus, bevacizumab had antitumor effects in a xenograft model of CHP.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）